These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Control of accelerated vein graft atheroma with the nitric oxide precursor: L-arginine. Davies MG; Dalen H; Kim JH; Barber L; Svendsen E; Hagen PO J Surg Res; 1995 Jul; 59(1):35-42. PubMed ID: 7630134 [TBL] [Abstract][Full Text] [Related]
23. Local delivery of a tissue factor antibody reduces early leukocyte infiltration but fails to limit intimal hyperplasia in experimental vein grafts. Annex BH; Davies MG; Fulton GJ; Huynh TT; Channon KM; Ezekowitz MD; Hagen PO J Surg Res; 1998 Dec; 80(2):164-70. PubMed ID: 9878308 [TBL] [Abstract][Full Text] [Related]
24. Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts. Kodama A; Komori K; Kajikuri J; Itoh T J Vasc Surg; 2009 Sep; 50(3):617-25. PubMed ID: 19700096 [TBL] [Abstract][Full Text] [Related]
25. Suppression of intimal hyperplasia in experimental vein grafts by oral l-arginine supplementation and single ex vivo immersion in deferoxamine manganese. Davis MG; Dalen H; Austerheim AM; Gulbrandsen TF; Svendsen E; Hagen PO J Vasc Surg; 1996 Mar; 23(3):410-20. PubMed ID: 8601882 [TBL] [Abstract][Full Text] [Related]
26. A comparative study of endothelium-derived relaxing factor-mediated relaxation and smooth muscle cell function in arterial and venous vein bypass grafts. Davies MG; Klyachkin ML; Svendsen E; Hagen PO Cardiovasc Surg; 1996 Apr; 4(2):150-60. PubMed ID: 8861428 [TBL] [Abstract][Full Text] [Related]
27. Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia. Osgood MJ; Sexton K; Voskresensky I; Hocking K; Song J; Komalavilas P; Brophy C; Cheung-Flynn J J Vasc Surg; 2016 Aug; 64(2):471-478. PubMed ID: 27763268 [TBL] [Abstract][Full Text] [Related]
28. Local effects of nitric oxide supplementation and suppression in the development of intimal hyperplasia in experimental vein grafts. Fulton GJ; Davies MG; Barber L; Gray JL; Svendsen E; Hagen PO Eur J Vasc Endovasc Surg; 1998 Apr; 15(4):279-89. PubMed ID: 9610339 [TBL] [Abstract][Full Text] [Related]
30. Control of the structural and functional consequences of vein graft intimal hyperplasia with a 21-aminosteroid--U74389G. Davies MG; Barber L; Dalen H; Svendsen E; Hagen PO Eur J Vasc Surg; 1994 Jul; 8(4):448-56. PubMed ID: 8088396 [TBL] [Abstract][Full Text] [Related]
32. The temporal sequence of G-protein expression in intimal hyperplasia. Davies MG; Barber L; Dhanraj DN; Gettys TW; Ramkumar V; Hagen PO J Surg Res; 1996 Jun; 63(1):115-22. PubMed ID: 8661183 [TBL] [Abstract][Full Text] [Related]
33. Local inhibition of tyrosine kinase activity markedly attenuates the development of intimal hyperplasia in experimental vein grafts. Huynh TT; Davies MG; Barber L; Svendsen E; Hagen PO J Surg Res; 1998 Jul; 77(2):104-11. PubMed ID: 9733595 [TBL] [Abstract][Full Text] [Related]
34. Influence of perioperative storage solutions on long-term vein graft function and morphology. Davies MG; Hagen PO Ann Vasc Surg; 1994 Mar; 8(2):150-7. PubMed ID: 8198948 [TBL] [Abstract][Full Text] [Related]
35. Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts. Zou J; Zhang X; Yang H; Zhu Y; Ma H; Wang S Ann Vasc Surg; 2011 May; 25(4):538-46. PubMed ID: 21549923 [TBL] [Abstract][Full Text] [Related]
36. Kinetics of altered angiotensin II responses in experimental vein grafts. Davies MG; Hagen PO J Invest Surg; 1996; 9(6):423-32. PubMed ID: 8981215 [TBL] [Abstract][Full Text] [Related]